China Resources Boya Bio-pharmaceutical Group Co.,Ltd

Equities

300294

CNE100001FF1

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
31.64 CNY +2.10% Intraday chart for China Resources Boya Bio-pharmaceutical Group Co.,Ltd +5.54% -6.06%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
China Resources Boya Bio-Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for the Year 2023 CI
China Resources Boya Bio-Pharmaceutical Group Co.,Ltd Proposes Cash Dividend CI
CR Boya Bio-Pharmaceutical's 2023 Profit Falls on Lower Revenue MT
China Resources Boya Bio-pharmaceutical Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CR Boya Bio-Pharmaceutical Signs 29.5 Million Yuan Construction Contract for Blood Products Facility MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. completed the acqyusution 89.681% stake in Guizhou Tianan Pharmaceutical Company from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd. CI
CR Boya Bio-Pharmaceutical's January-September Profit Increases MT
China Resources Boya Bio-pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. agreed to acquire an 89.681% stake in Guizhou Tianan Pharmaceutical Company from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd for CNY 260 million CI
China Resources Pharmaceutical Commercial Group Company Limited completed the acquisition of 75% stake in Guangdong Fuda Pharmaceutical Co., Ltd. from China Resources Boya Bio-pharmaceutical Group Co., Ltd.. CI
China Resources Pharmaceutical Commercial Group Company Limited agreed to acquire 75% stake in Guangdong Fuda Pharmaceutical Co., Ltd. from China Resources Boya Bio-pharmaceutical Group Co., Ltd. for approximately CNY 360 million. CI
China Resources Pharmaceutical's Subsidiaries Log Increases in H1 Profits MT
China Resources Boya's H1 Attributable Profit Jumps 16.9% MT
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
China Resources Boya Bio-pharmaceutical Group's Q1 Profit Rises MT
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2022, Payable on 28 April 2023 CI
CR Boya Bio-pharmaceutical Estimates Higher Q1 Profit MT
China Resources Boya Bio-Pharmaceutical Group Co., Ltd. Proposes Dividend for the Year 2022 CI
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
CR Boya Bio-pharmaceutical's January-September Profit Rises MT
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
China Resources Boya Bio-pharmaceutical Group Co., Ltd. announces the implementation of cash dividend for 2021, Payable on 13 May 2022 CI
China Resources Boya Bio-pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chart China Resources Boya Bio-pharmaceutical Group Co.,Ltd
More charts
China Resources Boya Bio-pharmaceutical Group Co Ltd, formerly Boya Bio-pharmaceutical Group Co Ltd, is a China-based company principally engaged in the research, development, production and distribution of blood products. The Company's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The Company's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The Company also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The Company distributes its products mainly in domestic market.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
31.64 CNY
Average target price
32.45 CNY
Spread / Average Target
+2.55%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300294 Stock
  4. News China Resources Boya Bio-pharmaceutical Group Co.,Ltd
  5. Boya Bio-Pharmaceutical’s Q3 Profit Doubles as Revenue Rises 13%; Shares Jump 4%